Press Releases and News

Landos Biopharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

November 26 2019

BLACKSBURG, Va., Nov. 26, 2019—Landos Biopharma today announced that Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer, will present at the following conference in New York:

Event: 31st Annual Piper Jaffray Healthcare Conference, Dec. 3-5, 2019
Location: Lotte New York Palace Hotel
Date/Time: Tuesday, Dec. 3, at 10:30 a.m. EST

About Landos Biopharma

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a first-in-class, oral therapeutic that acts locally in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD). The company has completed Phase 1 clinical testing and has initiated Phase 2 clinical testing of BT-11 for inflammatory bowel disease in 2019. Landos also has a robust pipeline of new compounds for other autoimmune diseases, several of which Landos anticipates will advance to Phase 1 clinical testing in 2020. Landos is headquartered in Blacksburg, Va. For more information, please visit

Chiara Russo (investors)
Solebury Trout

Rich Allan (media)
Solebury Trout